Prevention of atrial fibrillation by bucindolol is dependent on the beta1389 Arg/Gly adrenergic receptor polymorphism

JACC: Heart Failure

Volumn 1, Issue 4, 2013, Pages 338-344

  Aleong, Ryan G ^a   Sauer, William H ^a   Davis, Gordon ^b   Murphy, Guinevere A ^b   Port, J David ^b,c   Anand, Inder S ^d   Fiuzat, Mona ^e   O'Connor, Christopher M ^e   Abraham, William T ^f   Liggett, Stephen B ^g   Bristow, Michael R ^b,c,e  

^a UNIVERSITY OF COLORADO   (United States)

^b ARCA Biopharma   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Arrhythmia; Beta adrenergic receptors; Genetics; Heart failure; Norepinephrine

Indexed keywords

ARGININE; BETA 1 ADRENERGIC RECEPTOR; BUCINDOLOL; DNA; GLYCINE; NORADRENALIN; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART FAILURE WITH REDUCED LEFT VENTRICULAR EJECTION FRACTION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINUS RHYTHM; WILD TYPE;

ADRENERGIC BETA-ANTAGONISTS; ATRIAL FIBRILLATION; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROPANOLAMINES; PROSPECTIVE STUDIES; RECEPTORS, ADRENERGIC, BETA-1; TREATMENT OUTCOME;

EID: 84881556522     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2013.04.002     Document Type: Article

References (23)

1. Savelieva I., Camm A.J. Atrial fibrillation and heart failure: natural history and pharmacological treatment. Europace 2004, 5:S5-S19.
2. Benjamin E.J., Levy D., Vaziri S.M., D'Agostino R.B., Belanger A.J., Wolf P.A. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994, 271:840-844.
3. Wang T.J., Larson M.G., Levy D., et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003, 107:2920-2925.
4. Caldeira D., David C., Sampaio C. Rate versus rhythm control in atrial fibrillation and clinical outcomes: updated systematic review and meta-analysis of randomized controlled trials. Arch Cardiovasc Dis 2012, 105:226-238.
5. Saksena S, Slee A, Waldo AL, F etal. Cardiovascular outcomes in the affirm trial (atrial fibrillation follow-up investigation of rhythm management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses. J Am Coll Cardiol 2011;58:1975-85.
6. Bristow M.R. Treatment of chronic heart failure with β-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. Circ Res 2011, 109:1176-1194.
7. Nasr I.A., Bouzamondo A., Hulot J.S., Dubourg O., Le Heuzey J.Y., Lechat P. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J 2007, 28:457-462.
8. Eichhorn E.J., Bristow M.R. Medical therapy can improve the biologic properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation 1996, 94:2285-2296.
9. Arslan S., Erol M.K., Bozkurt E., et al. Effect of beta-blocker therapy on left atrial function in patients with heart failure: comparison of metoprolol succinate with carvedilol. Int J Cardiovasc Imaging 2007, 23:549-555.
10. Workman A.J., Kane K.A., Russell J.A., Norrie J., Rankin A.C. Chronic beta-adrenoceptor blockade and human atrial cell electrophysiology: evidence of pharmacological remodelling. Cardiovasc Res 2003, 58:518-525.
11. Liggett S.B., Mialet-Perez J., Thaneemit-Chen S., et al. Apolymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A 2006, 103:11288-11293.
12. 2C adrenergic receptor polymorphisms. PLoS One 2012, 7:e44324.
13. Aleong R.G., Sauer W.H., Robertson A.D., Liggett S.B., Bristow M.R. Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure. Circ Arrhythm Electrophysiol 2013, 6:137-143.
14. 2C-adrenergic receptor polymorphism alters the norepinephrine lowering effects and therapeutic response of the beta blocker bucindolol in chronic heart failure. Circ Heart Fail 2010, 3:21-28.
15. Atrial of the beta-adrenergic blocker bucindolol in patients with advanced heart failure. N Engl J Med 2001, 344:1659-1667. BEST Investigators.
16. Bristow M.R., Krause-Steinrauf H., Nuzzo R., et al. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial. Circulation 2004, 110:1437-1442.
17. Kao D.P., Davis G., MS, Aleong R., et al. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur J Heart Fail 2012, 15:324-333.
18. Tisdale J.E., Borzak S., Sabbah H.N., Shimoyama H., Goldstein S. Hemodynamic and neurohormonal predictors and consequences of the development of atrial fibrillation in dogs with chronic heart failure. JCard Fail 2006, 12:747-751.
19. Oral H., Crawford T., Frederick M., et al. Inducibility of paroxysmal atrial fibrillation by isoproterenol and its relation to the mode of onset of atrial fibrillation. JCardiovasc Electrophysiol 2008, 19:466-470.
20. Sharifov O.F., Fedorov V.V., Beloshapko G.G., Glukhov A.V., Yushmanova A.V., Rosenshtraukh L.V. Roles of adrenergic and cholinergic stimulation in spontaneous atrial fibrillation in dogs. JAm Coll Cardiol 2004, 43:483-490.
21. Wang C., Zhang Y.J., Wang Y.L., et al. Effect of dipfluzine on delayed afterdepolarizations and triggered activity induced by isoprenaline in human atrial fibers. Acta Pharmaceut Sinica 2006, 41:184-187.
22. van Veldhuisen D.J., Aass H., El Allaf D., Dunselman P.H., Gullestad L., Halinen M., Kjekshus J., Ohlsson L., Wedel H., Wikstrand J. Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF study. Eur J Heart Fail 2006, 8:539-546. MERIT-HF Study Group.
23. White H.L., de Boer R.A., Maqbool A., et al. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail 2003, 5:463-468.